journal article·2020-10Open access

LipoBots: Using Liposomal Vesicles as Protective Shell of Urease‐Based Nanomotors

Ana C. Hortelão, Sonia García‐Jimeno, Mary Cano‐Sarabia, Tania Patiño, Daniel Maspoch, Samuel Sanchez

Advanced Functional Materials· Volume 30· Issue 42

Abstract

Abstract Developing self‐powered nanomotors made of biocompatible and functional components is of paramount importance in future biomedical applications. Herein, the functional features of LipoBots (LBs) composed of a liposomal carrier containing urease enzymes for propulsion, including their protective properties against acidic conditions and their on‐demand triggered activation, are reported. Given the functional nature of liposomes, enzymes can be either encapsulated or coated on the surface of the vesicles. The influence of the location of urease on motion dynamics is first studied, finding that the surface‐urease LBs undergo self‐propulsion whereas the encapsulated‐urease LBs do not. However, adding a percolating agent present in the bile salts to the encapsulated‐urease LBs triggers active motion. Moreover, it is found that when both types of nanomotors are exposed to a medium of similar pH found in the stomach, the surface‐urease LBs lose activity and motion capabilities, while the encapsulated‐urease LBs retain activity and mobility. The results for the protection enzyme activity through encapsulation within liposomes and in situ triggering of the motion of LBs upon exposure to bile salts may open new avenues for the use of liposome‐based nanomotors in drug delivery, for example, in the gastrointestinal tract, where bile salts are naturally present in the intestine.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Micro and Nano Robotics · Advanced Materials and Mechanics · Supramolecular Self-Assembly in Materials

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute for Bioengineering of Catalonia (IBEC) The Barcelona Institute of Science and Technology (BIST) Baldiri i Reixac 10‐12 Barcelona 08028 Spain

Catalan Institute of Nanoscience and Nanotechnology (ICN2) CSIC and The Barcelona Institute of Science and Technology Universitat Autonoma de Barcelona Bellaterra Barcelona 08193 Spain

Chemistry Department University of Rome Tor Vergata Via della Ricerca Scientifica Rome 00133 Italy

Institució Catalana de Recerca i Estudis Avancats (ICREA) Passeig Lluís Companys 23 Barcelona 08010 Spain

Funding

Ministerio de Economía y Competitividad · Fundación BBVA · Generalitat de Catalunya · FP7 People: Marie-Curie Actions · Agència de Gestió d'Ajuts Universitaris i de Recerca

References (72)

Show source-provided references
1. 10.1021/acs.accounts.8b0051110.1021/acs.accounts.8b00511 ↗
2. 10.1021/acs.chemrev.5b0004710.1021/acs.chemrev.5b00047 ↗
3. 10.1021/acs.accounts.6b0038610.1021/acs.accounts.6b00386 ↗
4. 10.1002/anie.20190773310.1002/anie.201907733 ↗
5. 10.1021/acs.langmuir.9b0119210.1021/acs.langmuir.9b01192 ↗
6. 10.1021/acs.langmuir.5b0420610.1021/acs.langmuir.5b04206 ↗
7. 10.1021/la500819r10.1021/la500819r ↗
8. 10.1039/C1SM06512B10.1039/C1SM06512B ↗
9. 10.1039/C2NR32798H10.1039/C2NR32798H ↗
10. 10.1021/nn204762w10.1021/nn204762w ↗
11. 10.1002/adma.20150432710.1002/adma.201504327 ↗
12. 10.1002/chem.20180418910.1002/chem.201804189 ↗
13. 10.1021/acsami.7b0640210.1021/acsami.7b06402 ↗
14. 10.1002/smll.20180091210.1002/smll.201800912 ↗
15. 10.1039/C7EN00367F10.1039/C7EN00367F ↗
16. 10.1021/jacs.8b0576210.1021/jacs.8b05762 ↗
17. 10.1002/adma.20170366010.1002/adma.201703660 ↗
18. 10.1039/C9TA06290D10.1039/C9TA06290D ↗
19. 10.1021/acs.nanolett.8b0479410.1021/acs.nanolett.8b04794 ↗
20. 10.1021/nn305372n10.1021/nn305372n ↗
21. 10.1039/C5CC04120A10.1039/C5CC04120A ↗
22. 10.1016/j.coelec.2018.06.00410.1016/j.coelec.2018.06.004 ↗
23. 10.1126/scirobotics.aam643110.1126/scirobotics.aam6431 ↗
24. 10.1039/C6CS00885B10.1039/C6CS00885B ↗
25. 10.1002/adtp.20180005610.1002/adtp.201800056 ↗
26. 10.1021/acsnano.7b0834410.1021/acsnano.7b08344 ↗
27. 10.1002/adfm.20170564010.1002/adfm.201705640 ↗
28. 10.1126/scirobotics.aax061310.1126/scirobotics.aax0613 ↗
29. 10.1021/acsnano.8b0661010.1021/acsnano.8b06610 ↗
30. 10.1002/adma.20197019210.1002/adma.201970192 ↗
31. 10.1002/adfm.20170611710.1002/adfm.201706117 ↗
32. 10.1002/adtp.20190012510.1002/adtp.201900125 ↗
33. 10.1002/adfm.20170508610.1002/adfm.201705086 ↗
34. 10.1021/acsnano.9b0670610.1021/acsnano.9b06706 ↗
35. 10.1021/acsnano.6b0410810.1021/acsnano.6b04108 ↗
36. 10.1021/acs.accounts.8b0028810.1021/acs.accounts.8b00288 ↗
37. 10.1021/acscentsci.6b0025410.1021/acscentsci.6b00254 ↗
38. 10.1021/acsnano.5b0806710.1021/acsnano.5b08067 ↗
39. 10.1021/acs.nanolett.5b0310010.1021/acs.nanolett.5b03100 ↗
40. 10.1021/jacs.6b0685710.1021/jacs.6b06857 ↗
41. 10.1021/acs.nanolett.9b0183010.1021/acs.nanolett.9b01830 ↗
42. 10.1038/s41565-019-0578-810.1038/s41565-019-0578-8 ↗
43. 10.1021/jacs.8b0346010.1021/jacs.8b03460 ↗
44. 10.1038/s41467-019-10726-810.1038/s41467-019-10726-8 ↗
45. 10.1021/acsnano.5b0768910.1021/acsnano.5b07689 ↗
46. 10.1002/anie.20190069710.1002/anie.201900697 ↗
47. 10.1021/acsnano.9b0335810.1021/acsnano.9b03358 ↗
48. 10.1038/s41467-019-13288-x10.1038/s41467-019-13288-x ↗
49. 10.1039/C8PY00559A10.1039/C8PY00559A ↗
50. 10.1021/am502458h10.1021/am502458h ↗
51. 10.1016/j.addr.2018.09.00510.1016/j.addr.2018.09.005 ↗
52. 10.1016/j.ijpharm.2019.11872210.1016/j.ijpharm.2019.118722 ↗
53. 10.1016/j.addr.2018.05.00810.1016/j.addr.2018.05.008 ↗
54. 10.1021/mp100149j10.1021/mp100149j ↗
55. 10.1046/j.1365-2818.1997.1960757.x10.1046/j.1365-2818.1997.1960757.x ↗
56. 10.1021/la904194a10.1021/la904194a ↗
57. 10.1039/C4SM00981A10.1039/C4SM00981A ↗
58. Bangham A. D. · 1974 · 1
59. 10.1146/annurev.bb.09.060180.00234310.1146/annurev.bb.09.060180.002343 ↗
60. 10.1016/j.ijpharm.2007.04.03510.1016/j.ijpharm.2007.04.035 ↗
61. Sumner J. B. · J. Am. Chem. Soc. · 1929 · 149 · 1925
62. 10.1016/0003-2697(85)90442-710.1016/0003-2697(85)90442-7 ↗
63. 10.1021/ja01685a50210.1021/ja01685a502 ↗
64. J. D.Harvey Lodish A.Berk S.Lawrence Zipursky P.Matsudaira D.Baltimore inMolecular Cell Biology(Ed:W. H.Freeman) New York2000 Chap. 15.
65. 10.1039/C6RA16015H10.1039/C6RA16015H ↗
66. 10.1016/j.biomaterials.2004.02.02010.1016/j.biomaterials.2004.02.020 ↗
67. 10.1016/j.jcis.2010.04.06910.1016/j.jcis.2010.04.069 ↗
68. 10.1007/s11095-005-8476-110.1007/s11095-005-8476-1 ↗
69. FDA Administration Guidance for Industry Bioavailability and Bioequivalence Studies for Orally Administered Drug Products—General Guidance for Industry Bioavailability and Bioequivalence FDA Guidelines FDA Silver Spring MD2002 pp.1–24.
70. 10.1016/j.colsurfb.2016.07.04310.1016/j.colsurfb.2016.07.043 ↗
71. 10.1016/j.colsurfa.2009.04.05110.1016/j.colsurfa.2009.04.051 ↗
72. 10.1021/ac50011a03410.1021/ac50011a034 ↗